新股消息 | 新荷花递表港交所 公司为中国头部中药饮片产品供应商 中药饮片行业排名第二

Core Viewpoint - Sichuan Xinhehua Traditional Chinese Medicine Decoction Pieces Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with GF Securities (Hong Kong) and Agricultural Bank of China International as joint sponsors [1] Company Overview - Xinhehua is one of the largest suppliers of traditional Chinese medicine decoction pieces in China, ranking second in the market with a 0.4% market share as of 2024, according to Frost & Sullivan [4] - The company is the fastest-growing among the top five market participants, with a compound annual growth rate (CAGR) of 27% in revenue from 2022 to 2024 [4] Business Strategy - The company employs a dual-pillar strategy that balances its leadership in the core traditional Chinese medicine market with rapid response solutions for modern consumers [4] - Xinhehua serves over 1,000 hospitals and medical institutions, as well as large chain pharmacies, small pharmacies, clinics, and operators through offline channels [4] - The company aims to tap into global opportunities by exporting herbal products and establishing localized operations in high-potential international markets [4] Market Potential - The market for traditional Chinese medicine decoction pieces is projected to reach RMB 306.7 billion in 2024, making it the fastest-growing segment in the pharmaceutical industry [5] - Xinhehua's revenue comes from over 770 types and 4,900 categories of decoction pieces, with significant contributions from toxic decoction pieces such as Banxia and Jiangbanxia, as well as common decoction pieces like Chuanbeimu, Maidong, and Danggui [5] Financial Performance - Xinhehua's revenue for the years ending December 31 for 2022, 2023, and 2024, as well as for the six months ending June 30, 2024, and 2025, is as follows: - 2022: RMB 780 million - 2023: RMB 1.145 billion - 2024: RMB 1.249 billion - 2024 (six months): RMB 599 million - 2025 (six months): RMB 633 million [5][6] - The company's profits for the same periods are: - 2022: RMB 77.4 million - 2023: RMB 104.0 million - 2024: RMB 89.1 million - 2024 (six months): RMB 42.7 million - 2025 (six months): RMB 51.2 million [5][6]